Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;197(3):339-348.
doi: 10.1111/bjh.18089. Epub 2022 Feb 21.

Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response?

[Article in Spanish]
Anita Frisanco Oliveira  1   2 , Aline Tansini  1   3 , Thais Toledo  1   3 , Rafael Balceiro  1 , Maria Lucia Martino Lee  2 , Neysimelia Villela  4   5 , Patricia Ikeuty  5 , Konradin Metze  6 , Luiz Fernando Lopes  1   7 , Irene Lorand-Metze  3   8
Affiliations

Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response?

[Article in Spanish]
Anita Frisanco Oliveira et al. Br J Haematol. 2022 May.

Abstract

5-Azacitidine has been used before stem cell transplantation in juvenile myelomonocytic leukaemia (JMML) patients. Recently, we have described immunophenotypic features in JMML at diagnosis. Here, our aim was to examine the changes in the immunophenotypic features during azacitidine treatment, correlating it with clinical response. Patients treated with 5-azacitidine were evaluated at diagnosis and after three and six cycles of medication. Among 32 patients entering the study, 28 patients were examined after three cycles and 25 patients after six. Patients showed a reduction in CD34/CD117+ cells: median 3.35% at diagnosis, 2.8% after three cycles and 1.63% after six. B-cell progenitors were decreased at diagnosis and decreased after treatment. Monocytes decreased: 11.91% to 6.4% and 4.18% respectively. Complete response was associated with increase in classical monocytes. T lymphocytes, reduced at diagnosis, increased in patients responding to 5-azacitidine. Immunophenotypic aberrancies including expression of CD7 in myeloid progenitors remained after treatment. This feature was associated with a worse response to treatment, as well as presence of NF1. Immunophenotyping was feasible in all patients. Clinical response was associated with a decrease of myeloid progenitors and monocytes and a rise in T lymphocytes although phenotypic aberrancies persisted. The largest effect was observed after three cycles.

Keywords: azacytidine; immunophenotyping; juvenile myelomonocytic leukaemia; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Aricó M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90:479-88.
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
    1. Niemeyer C, Aricó M, Basso G, Biondi A, Rajnoldi AC, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997;89(10):3534-43.
    1. Vidal DO, Paixão MB, Souto EX, Caballero OL, Lopes LF, Vettore AL. Aberrant methylation in pediatric myelodysplastic syndrome. Leukemia Res. 2007;31(2):175-81.
    1. Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Lipka D, et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2127.

Publication types

LinkOut - more resources